Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>OvaWatch mass monitoring completes OvaSuite portfolio.</li><li>With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass.</li><li>Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.</li></ul>

OvaWatch mass monitoring completes OvaSuite portfolio.With the recent launch of longitudinal or serial adnexal mass monitoring for OvaWatch, physicians and patients could assess ongoing malignancy risk for all women with a mass.Collaboration opportunities for biobank. Aspira completed a full inventory of its biobank, identifying about 70K patient samples, which would be available for secondary research and potential collaboration opportunities. The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.

Aspira Women's Health, Inc. - Water Tower Hour Recap

<ul><li>Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.</li><li>Dr. Milligan will report to CEO Nicole Sandford. She has more than 25 years of experience in the healthcare sector, with corporate experience that includes executive roles at biopharmaceutical companies Amgen, Genentech, Merck, and Organon.</li><li>Dr. Milligan supported pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health. </li></ul>

Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.Dr. Milligan will report to CEO Nicole Sandford. She has more than 25 years of experience in the healthcare sector, with corporate experience that includes executive roles at biopharmaceutical companies Amgen, Genentech, Merck, and Organon.Dr. Milligan supported pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health. 

Aspira Women's Health, Inc. - Aspira Women's Health Expands Senior Leadership Team

<ul><li>Aspira Women’s Health hosted an R&amp;D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.</li><li>CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD.</li><li>Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion.</li></ul>

Aspira Women’s Health hosted an R&amp;D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.CEO Nicole Sandford led the discussion, and was joined by Chief Scientific Officer Dr. Jody Berry, PhD, and one of Aspira’s medical advisors and research partners, Dr. Kevin Elias, MD.Aspira also discussed the domestic market potential for both ovarian cancer and endometriosis products, which it estimates is more than $1.5 billion.

Aspira Women's Health, Inc. - Aspira Women's Health Hosts R&D Day

<ul><li>Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October.</li><li>This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma.</li><li>Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis.</li></ul>

Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The University of Oxford in October.This data shows EndoCheck to be a high-performing blood test for localized endometriosis, including ovarian endometriosis masses known as endometrioma.Endometrioma is a localized form of endometriosis that has formed an ovarian mass. It is one of the most common types of endometriosis.

Aspira Women's Health, Inc. - Provides Important Update on EndoCheck Diagnostic Test

<ul><li>Aspira Women’s Health made two reimbursement announcements this week.</li><li>On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1.</li><li>Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. </li></ul>

Aspira Women’s Health made two reimbursement announcements this week.On November 27, Aspira announced that the Centers for Medicare and Medicaid Services (CMS) approved the crosswalk of the fee to be paid to the company for OvaWatch to the fee paid historically for Ova1.Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements beginning on January 1, 2024. 

Aspira Women's Health, Inc. - Secures Important Reimbursements

United States

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aspira Women's Health (AWH US)

Aspira Women's Health, Inc. - Water Tower Hour Recap

The biobank is a significant competitive advantage in developing solutions for ovarian cancer and other gynecologic diseases.

Water Tower Research

Aspira Women's Health, Inc. - Aspira Women's Health Expands Senior Leadership Team

Aspira Women’s Health expands senior management team with the addition of Sandra Milligan, MD, JD as President effective April 1, 2024.

Water Tower Research

Aspira Women's Health, Inc. - Aspira Women's Health Hosts R&D Day

Aspira Women’s Health hosted an R&D Day and discussed updates on its non-invasive diagnostic platforms for ovarian cancer and endometriosis.

Water Tower Research

Aspira Women's Health, Inc. - Provides Important Update on EndoCheck Diagnostic Test

Aspira Women’s Health announced today that it has completed the design of the EndoCheck test based on the analysis of samples received from The...

Water Tower Research

Aspira Women's Health, Inc. - Secures Important Reimbursements

Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)